<DOC>
	<DOCNO>NCT00546819</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , immunogenicity ZOSTAVAX™ patient receive chronic/maintenance corticosteroid .</brief_summary>
	<brief_title>ZOSTAVAX™ Patients Chronic/Maintenance Corticosteroids ( V211-017 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Varicellahistory positive , herpes zoster ( HZ ) history negative patient 60 year age old receive chronic/maintenance systemic corticosteroid therapy daily dose 5 20 mg prednisone equivalent least 2 week immediately prior enrollment expect continue receive daily dose 5 20 mg prednisone equivalent 6week primary safety followup period ( dose may vary within range 6week postvaccination period ) All female enrol must postmenopausal Patients history hypersensitivity reaction gelatin neomycin Prior receipt varicella zoster vaccine ; prior history herpes zoster Immune globulin and/or blood product give within 5 month prior expect within 6week postvaccination period Receipt live virus vaccination within 1 month receipt inactivate vaccination within 7 day prior enrollment Known immune deficiency cause medical condition Any use 8 week prior vaccination 6 week vaccination medication may suppress immune system include methotrexate , corticosteroid daily dose great 20 mg prednisone equivalent , agent use treat cancer , medication alter level immune response use treat arthritis illness Concomitant use antiviral therapy A history alcohol abuse recreational drug use</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>